Data Sheet (Cat.No.T14078)

AB928

Chemical Properties



CAS No. : 2239273-34-6

Formula: C23H22N8O

Molecular Weight: 426.47

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AB928 is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. It has immunomodulatory activity[1].
Targets(IC50)	Adenosine Receptor

Solubility Information

Solubility	DMSO: 250 mg/mL (586.21 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.74 mM),Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (23.45 mM),Solution. 10% DMSO+90% Saline: < 10 mg/mL (23.45 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3448 mL	11.7242 mL	23.4483 mL
5 mM	0.469 mL	2.3448 mL	4.6897 mL
10 mM	0.2345 mL	1.1724 mL	2.3448 mL
50 mM	0.0469 mL	0.2345 mL	0.469 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Seitz L, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. 2019 Aug;37(4):711-721.